NCT06633224 Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
| NCT ID | NCT06633224 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2024-12-27 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2024-12-27 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.
Eligibility Criteria
Inclusion Criteria: * Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX). * Participants receiving \>= 15 fractions. * Participants is male or female and is \>18 years of age on the day of signing the informed consent. * Ability to understand a written informed consent document. * Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment. * Willing to have medical records reviewed for clinical information. * Able to read, write and understand English or Spanish. Exclusion Criteria: * Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).
Contact & Investigator
Sue Yom, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06633224 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06633224 currently recruiting?
Yes, NCT06633224 is actively recruiting participants. Contact the research team at Jamese.Johnson@ucsf.edu for enrollment information.
Where is the NCT06633224 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06633224 clinical trial?
NCT06633224 is sponsored by University of California, San Francisco. The principal investigator is Sue Yom, MD at University of California, San Francisco. The trial plans to enroll 125 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.